Advanz Pharma Corp. buy DomRuinart
Summary
This prediction ended on 10.04.17 with a price of €381.48. The BUY prediction by DomRuinart for Advanz Pharma Corp. performed very badly with a performance of -68.36%. DomRuinart has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Advanz Pharma Corp. | - | - | - | - |
| iShares Core DAX® | -0.793% | 4.201% | 19.951% | 70.602% |
| iShares Nasdaq 100 | -2.376% | 0.857% | 4.704% | 103.322% |
| iShares Nikkei 225® | -2.701% | -0.147% | 12.609% | 44.593% |
| iShares S&P 500 | -1.689% | 1.244% | 3.144% | 64.741% |
Comments by DomRuinart for this prediction
In the thread Advanz Pharma Corp diskutieren
short-squeeze ante portas:
Okay, hier wird fleißig auf eine Insolvenz hingeshorted. Soll mir mal einer erklären wie es bei den Zahlen zu einer Insolvenz kommen soll:
Cash balalance at end of Q2: $145M
EBITDA for 6 months: $240M
Net Note Proceeds: $325M
Interest on Existing Debt: USD$120M
Principal on Existing Debt: USD$20M
Interest on new $350M Notes: USD $7M
First Cinven Instalment: $88
145 +240 + 325 -120 - 20- 7 -88=$475M
entsprechend
Cash balalance at beginning of 2017: $475M
EBITDA for 2017: $480M
Interest on existing debt: $240M
Principal on Existing Debt: $40M
Interest on new $350M Notes: $31.5M
Principal on New notes: $10M
Second Cinven Instalment: $94
475+480-240-40-31.5-10-94=$539.5M
Das ganze abgesichert mit einen $200M Revolver Credit
Ich glaube hier eher an ein baldiges buy-out und spekuliere auf einen veritablen short-squeeze...